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Background
The Clinical Program of the Ludwig Institute for Cancer
Research (LICR) aims to translate basic laboratory dis-
coveries into early phase clinical trials in cancer patients.
A key component of the LICR approach has been to
focus on the identification of antibodies selectively tar-
geting antigens preferentially expressed in tumour tissue,
and the molecular engineering of chimeric or huma-
nised antibodies to these targets. The development of
robust and high producing cell lines is crucial in the
development of each antibody construct. The Cell Biol-
ogy Group at the LICR Melbourne-Austin Branch is
responsible for the production of recombinant proteins
including monoclonal antibodies from hybridomas or
from industrially relevant mammalian cell lines (CHO,
NS0, etc). The Cell Line Development activities are dri-
ven by the successful combination of industrial relevant
cell lines transfected with cancer-relevant DNA targets
using the Glutamine-Synthetase system (GS) from
Lonza. Here we present two case-studies of high-pro-
ductive cell lines in terms of product quality and biolo-
gical activity of the protein produced with these cell
lines.
Material and methods
Cell line development / Production: CHO-K1 SV cells
were transfected with the vector coding for monoclonal
antibody LICR A within a GS expression vector (Lonza)
and maintained in CD-CHO (Invitrogen) + 25μM
methionine sulfoximine (MSX) (Sigma). LICR B (mu)
murine hybridomas were generated against LICR B anti-
gen and maintained in DMEM + 15% FBS (Invitrogen).
Shake flask productivity screens were performed in E250
Erlenmeyer flasks with CD-CHO + 25μM MSX in batch
mode for LICR A and LICR B and fed-batch for LICR
B. Bioreactor productions: LICR A : 15L stirred-tanks
bioreactors (STR) (Applikon) in batch mode + tempera-
ture shift in CD-CHO 32μM MSX; LICR B (mu): 15L
STR in batch mode + temperature shift in DMEM (Invi-
trogen) + 15% FBS and LICR B : 7L STR (Applikon) in
fed-batch mode + temperature shift in CD-CHO +
32μM MSX. Purification: Supernatants were filtered and
purified with Protein A eluted with 100mM glycine (pH
2.5), then adjusted to pH 8.0 with 1M Tris buffer then
dialysed into PBS. ELISA assay: An anti-human IgG (g-
chain specific) antibody for coating plates and an anti-
human IgG (g-chain specific) alkaline phosphatase con-
jugate as secondary antibody. Purified antibody was used
to set up a standard curve for calculating antibody con-
centration. Plates were read at 405 nm.
SDS PAGE: Antibody (5μg) in a final volume of 20μl
was loaded under both reducing and non-reducing con-
ditions on NuPage, 4-12% Bis-Tris gels (Invitrogen)
along with 20μl of molecular weight standards. Protein
bands were detected with Coomassie blue staining. Bio-
sensor analyses were conducted on a BIAcore 2000
instrument (GE). The epitope for the recombinant anti-
body was immobilized in a Ni-NTA chip and a blank
control channel was for correction of refractive index
effects. Sample at increasing concentrations were flowed
over the chip surface and then washed out. The chip
was regenerated with 0.1M EGTA between each analy-
sis. FACS analysis was performed with a FACS Canto II
cytometer (Becton Dickinson), Cell line expressing anti-
gen A at 5x105cells/sample; Negative control: isotype
IgG (10μg /mL); Positive control: Purified LICR A
(10μg/mL); Secondary antibody PE conjugated (1:1000)
(Sigma); Data analysis using Gatelogic v 3.08 (Inivai).
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Results – discussion
LICR A: Production of the LICR A antibody increased
from 265 mg/L in shake-flask production to 721 mg/L
in 15L bioreactor (Results not shown). The FACS analy-
sis of LICR A antibody with cells expressing the A anti-
gen shows an increased binding when using purified
LICR A antibody from the bioreactor production at 50
μg/mL (Mean Fluorescent Intensity (MFI) for PE from
LICR A shake flask: 4591 and MFI PE from LICR A
bioreactor: 9396). Physicochemical analysis by SDS-
PAGE of the product shows that the heavy and light
chains (under reduced conditions) and the banding pat-
tern (under non-reduced conditions) are typical for IgG.
On SE-HPLC the main peak (94.7% for shake flask and
91.1% for bioreactor) is eluting at the expected size of
an intact IgG.
LICR B: Production of the LICR B antibody showed a
continued increase from the production in bioreactor of
the parental LICR B (mu): 109 mg/L to 537 mg/L in
shake-flask batch mode and to 1252 mg/L in shake-flask
fed-batch mode (Results not shown). The highest pro-
ductivity observed by ELISA was observed with the
supernatant from the 7L bioreactor in fed-batch mode:
2244 mg/L. The BIAcore comparative analysis of the
material purified from the LICR B (mu) bioreactor and
LICR B bioreactor fed-batch shows an increased binding
(decreased Kd) : Kd LICR B (mu) bioreactor: 0.41 nM;
Kd LICR B bioreactor fed-batch: 1.13 pM (Figure 1).
Physicochemical analysis by SDS-PAGE of the product
shows that the heavy and light chains (under reduced
conditions) and the banding pattern (under non-reduced
conditions) are typical for IgG. On SE-HPLC the main
Figure 1 Binding to cells expressing the LICR A antigen analysed by FACS for purified LICR A antibody and Binding to LICR B antigen-coated
chips analysed by BIAcore for purified LICR B antibody.
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peak [96.8% for LICR B (mu) and 95.9% for LICR B] is
eluting as an intact IgG (Results not shown).
Conclusion
We have successfully constructed two GS-CHO cell
lines producing functional intact antibodies against can-
cer-related epitopes. The product concentration was
substantially increased for both cell lines without having
a negative effect of product quality. Analyses of complex
glycans present on LICR A and LICR B antibodies are
to be performed.
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